Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer

被引：53

作者：

Helm, C. William ^{[1
]}

Bristow, Robert E. ^{[2
]}

Kusamura, Shigeki ^{[3
]}

Baratti, Dario ^{[3
]}

Deraco, Marcello ^{[3
]}

机构：

[1] Univ Louisville, James Graham Brown Canc Ctr, Div Gynecol Oncol, Louisville, KY 40207 USA

[2] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Kelly Gynecol Oncol Serv, Baltimore, MD 21205 USA

[3] Natl Canc Inst, Dept Surg, I-20133 Milan, Italy

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2008年 / 98卷 / 04期

关键词：

hyperthermic intraperitoneal chemotherapy; cytoreductive surgery; epithelial ovarian cancer; hyperthermia; loco-regional therapy; intraperitoneal chemotherapy;

D O I：

10.1002/jso.21083

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Women with epithelial ovarian cancer (EOC) usually present with advanced disease and overall only just over half survive 5 years. Even following a complete response to front-line treatment two-thirds will recur, with a resultant dismal prognosis. We review and discuss the role of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in EOC and present the results of the ovary consensus panel (OCP) convened for the 5th International Workshop on Peritoneal Surface Malignancy.

引用

页码：283 / 290

页数：8

共 96 条

[1]

Ajisaka H, 2002, HEPATO-GASTROENTEROL, V49, P1027

[2] IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].

ALBERTS, DS ;

GREEN, S ;

HANNIGAN, EV ;

OTOOLE, R ;

STOCKNOVACK, D ;

ANDERSON, P ;

SURWIT, EA ;

MALVLYA, VK ;

NAHHAS, WA ;

JOLLES, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717

[3] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[4]

ALBERTS DS, 1980, J NATL CANCER I, V65, P455

[5]

ALBERTS DS, 1992, J CLIN ONCOL, V10, P1505

[6]

[Anonymous], PRACTICAL GYNECOLOGI

[7] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[8] Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer [J].

Axtell, Allison E. ;

Lee, Margaret H. ;

Bristow, Robert E. ;

Dowdy, Sean C. ;

Cliby, William A. ;

Raman, Steven ;

Weaver, John P. ;

Gabbay, Mojan ;

Ngo, Michael ;

Lentz, Scott ;

Cass, Ilana ;

Li, Andrew J. ;

Karlan, Beth Y. ;

Holschneider, Christine H. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) :384-389

[9] A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment [J].

Barakat, RR ;

Almadrones, L ;

Venkatraman, ES ;

Aghajanian, C ;

Brown, C ;

Shapiro, F ;

Curtin, JP ;

Spriggs, D .

GYNECOLOGIC ONCOLOGY, 1998, 69 (01) :17-22

[10] Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up [J].

Barakat, RR ;

Sabbatini, P ;

Bhaskaran, D ;

Revzin, M ;

Smith, A ;

Venkatraman, E ;

Aghajanian, C ;

Hensley, M ;

Soignet, S ;

Brown, C ;

Soslow, R ;

Markman, M ;

Hoskins, WJ ;

Spriggs, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :694-698

← 1 2 3 4 5 6 7 8 9 10 →